DCX and Alzheimer disease: Bassani et al. reported that an ICV injection of STZ (an animal model of AD) increased immunoreactivity of the glial markers Iba-1 and GFAP and decreased cell proliferation and the number of immature neurons (Ki-67+ and DCX+ cell) in the SVZ and dentate gyrus of the hippocampus [177].